Aficamten (CK-274) demonstrates favorable pharmacokinetics by reaching steady state concentration within a two-week window, supporting its development for hypertrophic cardiomyopathy.
similar to predictions and was able to reach steady state concentration within the desired two-week window.
Chuang et al. (Mon,) studied this question.
Synapse has enriched 5 closely related papers on similar clinical questions. Consider them for comparative context: